Log In
BCIQ
Print this Print this
 

nusinersen (IONIS-SMNRx) (formerly ISIS-SMNRx)

  Manage Alerts
Collapse Summary General Information
Company Ionis Pharmaceuticals Inc.
DescriptionAntisense oligonucleotide that modulates splicing of survival of motor neuron 2 centromeric (SMN2) mRNA
Molecular Target Survival of motor neuron 2 centromeric (SMN2)
Mechanism of ActionAntisense therapy
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentPhase III
Standard IndicationSpinal muscular atrophy (SMA)
Indication DetailsTreat infantile-onset spinal muscular atrophy (SMA); Treat spinal muscular atrophy (SMA) in children; Treat spinal muscular atrophy (SMA) in children and infants
Regulatory Designation U.S. - Fast Track (Treat spinal muscular atrophy (SMA) in children);
U.S. - Orphan Drug (Treat spinal muscular atrophy (SMA) in children)
PartnerBiogen Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$299.0M

0

$270.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/09/2012

$299.0M

0

$270.0M

Get a free BioCentury trial today